Safety of aripiprazole: High serum levels in a CYP2D6 mutated patient [10]

American Journal of Psychiatry

Volumn 164, Issue 1, 2007, Pages 175-

  Oosterhuis, Marieke ^a   Van De Kraats, Gerben ^a   Tenback, Diederik ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; QUETIAPINE;

ADULT; AMNESIA; CASE REPORT; DNA MODIFICATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; LETHARGY; LETTER; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 33846507333     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.2007.164.1.175     Document Type: Letter

References (6)

1. Mallikaarjun S, Salazar DE, Bramer SL: Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004; 44: 179-187
2. Bristol-Myers Squibb BV: Aripiprazole Summary of Product Characteristics, 2004
3. Evans WE, Relling MV, Rahman A, McLeod HL, Scott EP, Lin JS: Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest 1993; 91:2150-2154
4. Mizutani T: PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 2003; 35:99-106
5. Carstairs SD, Williams SR: Overdose of aripiprazole, a new type of antipsychotic. J Emerg Med 2005; 28:311-313
6. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Deun K, Smith P, Berger B, Heller A: Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000; 32:56-67